Showing results (11-20 of 42) with videos related to
Sort By:
Pageof 5
The AAPS Journal|August 20, 2015
A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer PatientsAhmed Abbas Suleiman, Sebastian Frechen, Matthias Scheffler, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 17, 2014
Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinibAhmed Abbas Suleiman, Sebastian Frechen, Matthias Scheffler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study GroupKarolin Behringer, Kai Breuer, Thorsten Reineke, et al.Plos One|March 8, 2022
Reproducibility of dynamic contrast enhanced MRI derived transfer coefficient Ktrans in lung cancerJean-Philip Daniel Weber, Judith Eva Spiro, Matthias Scheffler, et al.Clinical Nuclear Medicine|October 3, 2012
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinibDeniz Kahraman, Arne Holstein, Matthias Scheffler, et al.Annals of Hematology|March 11, 2005
Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphomaJan-Peter Glossmann, Jan Oliver Staak, Lucia Nogova, et al.European Journal of Nuclear Medicine and Molecular Imaging|April 25, 2012
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinibCarsten Kobe, Matthias Scheffler, Arne Holstein, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 9, 2011
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PETDeniz Kahraman, Matthias Scheffler, Thomas Zander, et al.Journal of Neuro-Oncology|June 29, 2023
Radiomics for the non-invasive prediction of PD-L1 expression in patients with brain metastases secondary to non-small cell lung cancerAnna-Katharina Meißner, Robin Gutsche, Norbert Galldiks, et al.Plos One|January 12, 2013
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinibMatthias Scheffler, Thomas Zander, Lucia Nogova, et al.Pageof 5